Syros Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Syros Pharmaceuticals

16/05/2022 14:32

* Syros Pharmaceuticals Inc  SYRS.OQ  reported a quarterly
adjusted loss of 40 cents​​ per share for the quarter ended in
March. The mean expectation of seven analysts for the quarter
was for a loss of 47 cents per share.
    * Revenue rose 13.3% to $5.47 million from a year ago; 
analysts
expected $4.92 million. 
    * Syros Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 40 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Syros Pharmaceuticals Inc shares had fallen by 24.5% this
quarter and lost 72.4% so far this year.
    * The company reported a quarterly loss of $25.15 million.
    * Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 01:32 p.m.  ​All
figures in US dollars unless otherwise stated